Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

Francesca Chamian, Shao Lee Lin, Edmund Lee, Toyoko Kikuchi, Patricia Gilleaudeau, Mary Sullivan-Whalen, Irma Cardinale, Artemis Khatcherian, Inna Novitskaya, Knut M. Wittkowski, James G. Krueger, Michelle A. Lowes

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Abstract

Background: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. Methods: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. Results: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA-) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-γ-producing) were also significantly reduced. Conclusion: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.

Original languageEnglish (US)
Article number27
JournalJournal of Translational Medicine
Volume5
DOIs
StatePublished - Jun 7 2007

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis'. Together they form a unique fingerprint.

Cite this